photonamic became a 100% subsidiary of the SBI group in 2016 due to the growing interest of SBI to further the development of 5-ALA. In subsequent years, NX Development Corp, Photonics Healthcare and FerroSens have all been acquired to allow the group to focus on a global development system to facilitate research and development into the use of 5-ALA (5-aminolevulinic acid).
NX Development Corp was founded as a life sciences company dedicated to the commercial launch of Gleolan® in the United States. They are dedicated to advancing the knowledge and understanding of brain tumor visualization.
Photonics Healthcare (Photonics), a medical technology company is developing a novel technology for oxygen measurement in skin cells. Photonics’ COMET system combined with photonamic’s dermal 5-ALA patch have shown promising results as an innovative, non-invasive oxygen measurement system, which has potential benefits over existing techniques.
FerroSens has successfully developed FIDscreen, a simple and non-invasive iron deficiency testing device. FIDscreen is based on an optical method, fluorescence spectroscopy and an elaborate data evaluation to obtain a quantitative measurement of zinc protoporphyrin (ZnPP), an established marker for iron deficiency.
Combining the capabilities of 5-ALA as a precursor of protoporphyrin in combination with this technology will allow us to provide innovative solutions for the benefit of patients and health care professionals specifically in the field of oncology.
to see . to know . to heal
Eggerstedter Weg 12
25421 Pinneberg
Germany
Tel: +49 (4101) 785 39 09
Fax: +49 (4101) 784 94 02
Email: info@photonamic.de
